Clinical Trial Update: Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial evaluating donor-derived CD117 CAR-T cells for relapsed/refractory acute myeloid leukemia; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD117 CAR-T cells (donor-derived) (CD117 CAR-T cells)

Snippet

Sponsor: Zhejiang University | Conditions: Acute Myeloid Leukemia | EARLY_Phase 1 | Status: RECRUITING